Article
Version 1
Preserved in Portico This version is not peer-reviewed
Risk of Infections Associated with the Use of Monoclonal Antibodies in Multiple Myeloma (MM)
Version 1
: Received: 22 May 2024 / Approved: 22 May 2024 / Online: 23 May 2024 (08:17:48 CEST)
How to cite: Mele, G. Risk of Infections Associated with the Use of Monoclonal Antibodies in Multiple Myeloma (MM). Preprints 2024, 2024051458. https://doi.org/10.20944/preprints202405.1458.v1 Mele, G. Risk of Infections Associated with the Use of Monoclonal Antibodies in Multiple Myeloma (MM). Preprints 2024, 2024051458. https://doi.org/10.20944/preprints202405.1458.v1
Abstract
Patients with Multiple Myeloma have an increased susceptibility to severe infections due to several various factors, especially the high tumor burden. The use of the anti-CD38 monoclonal antibodies-based therapies has changed the frequency and epidemiology of infections. We report herein the safety profile of the pivotal clinical trials conducted with anti-CD38 mAbs (daratumumab and isatuximab) and anti-SLAMF7 mAbs (elotuzumab) that led to the approval of regimens employed today in NDMM and RRMM patients.
Keywords
infectious diseases, Multiple Myeloma, monoclonal antibody based-strategies
Subject
Medicine and Pharmacology, Hematology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment